Press Releases

April 26, 2018

Neuraltus Pharmaceuticals Reports Results from Phase 2 NP001 Study in Amyotrophic Lateral Sclerosis (ALS)

January 4, 2018

Neuraltus Pharmaceuticals Announces Completion of Last Patient Visit in Confirmatory Phase 2 Study of NP001 for the Treatment of Amyotrophic Lateral Sclerosis

September 13, 2017

Neuraltus Pharmaceuticals and the University of Hawaii at Manoa Announce Initiation of Phase 1b Study of NP001 in Patients with Mild-to-Moderate Alzheimer's Disease

July 12, 2017

Neuraltus Announces Completion of Enrollment in Confirmatory Phase 2 Study of NP001 in ALS Patients with Systemic Inflammation

April 3, 2017

Retrospective Analysis Finds Amyotrophic Lateral Sclerosis Patients with High Serum C-Reactive Protein (CRP) Levels May Respond to Immune Regulators Like NP001

February 8, 2017

Neuraltus Pharmaceuticals Provides Enrollment Update on Confirmatory Phase 2 Study of NP001 in ALS

September 22, 2016
Neuraltus Pharmaceuticals Initiates Confirmatory Phase 2 Study of NP001 in Patients with Amyotrophic Lateral Sclerosis

April 4, 2016
Neuraltus Pharmaceuticals Announces Plans for Second Phase 2 Study of NP001 in ALS Using Biomarker for Enriched Patient Selection

Biomarker Analyses of Neuraltus Pharmaceuticals’ NP001 Phase 2 Data Demonstrate Potential for Treating ALS Patients with Systemic Inflammation

September 21, 2015
Neuraltus Pharmaceuticals and Clinigen Group Announce Partnership to Initiate a Managed Access Program for Investigational ALS Therapy in Europe

July 1, 2015
Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001

April 20, 2015
Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals’ NP001 Potential Efficacy and Safety in ALS

December 9, 2013
Neuraltus Pharmaceuticals' NP001 Phase 2 Results Highlighted at the 24th International Symposium on ALS/MND

October 8, 2013
Neuraltus Pharmaceuticals Names Richard L. Casey as President and Chief Executive Officer

October 29, 2012
Neuraltus Pharmaceuticals Announces Phase 2 Clinical Results for NP001 in Patients with Amyotrophic Lateral Sclerosis (ALS)